Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Combination of Azelaic Acid 5% and Clindamycin 2% for the Treatment of Acne Vulgaris Publisher Pubmed



Pazokitoroudi H1, 2, 3 ; Nilforoushzadeh MA1, 4 ; Ajami M5 ; Jaffary F4 ; Aboutaleb N2 ; Nassirikashani M6 ; Firooz A6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Tehran University of Medical Sciences, Physiology Research Center, Tehran, Hemmat Street, Iran
  3. 3. Nano Vichar Pharmaceutical Ltd., Tehran, Iran Sciences, Tehran, Iran
  4. 4. Skin Diseases and Leishmaniasis Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Departments of Nutrition, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran

Source: Cutaneous and Ocular Toxicology Published:2011


Abstract

Context and objective: Acne vulgaris, an inflammatory skin disease with different clinical appearances, is a common problem in most adolescents. It seems that using combinations of topical agents can decrease resistance to the treatment and improve the efficacy. Therefore, we evaluated the effects of azelaic acid (AA) 5% and clindamycin (Clin) 2% combination (AA-Clin) on mild-to-moderate acne vulgaris. Materials and methods: The efficacy and safety of 12-week treatment with AA-Clin in patients with mild-to-moderate facial acne vulgaris were evaluated by a multicenter, randomized, and double-blind study. A total of 88 male and 62 female patients were randomly assigned to one of these treatments: AA 5%, Clin 2%, and combination of them. Every 4 weeks, total inflammatory and noninflammatory lesions were counted, acne severity index (ASI) was calculated, and patient satisfaction was recorded. Results: Treatment for 12 weeks with combination gel significantly reduced the total lesion number compared with baseline (p<0.01), as well as Clin 2% or AA 5% treatment groups (p<0.05 or p<0.01). The percentage of reduction in ASI in combination treated group (64.16±6.01) was significantly more than those in the Clin 2% (47.73±6.62, p<0.05) and 5% AA (32.46±5.27, p<0.01) groups after 12 weeks. Among the patients in the AA-Clin group, 75.86% of males were satisfied or very satisfied and 85.71% of females were satisfied or very satisfied. This trend was significant in comparison to the number of patients who were satisfied with AA 5% or Clin 2% treatment (p<0.01). Seven patients in AA-Clin group (incidence=22%) showed adverse effects that were not statistically significant compared to treatment with individual active ingredients. Discussion and conclusion: The profound reduction in lesion count and ASI by combination therapy with AA-Clin gel in comparison to individual treatment with 5% AA or Clin 2% suggested the combination formula as an effective alternative in treatment of acne vulgaris. © 2011 Informa Healthcare USA, Inc.
5. Efficacy of Topical Azelaic Acid Gel in the Treatment of Mild-Moderate Acne Vulgaris, Indian Journal of Dermatology, Venereology and Leprology (2007)
6. Association of Abo and Rhesus Blood Groups With Acne Vulgaris, Journal of Isfahan Medical School (2012)
Experts (# of related papers)
Other Related Docs
27. Topical Tranexamic Acid As a Promising Treatment for Melasma, Journal of Research in Medical Sciences (2014)
40. Role of Menthol in Treatment of Candidial Napkin Dermatitis, World Journal of Pediatrics (2011)
41. Can Subcision With the Cannula Be an Acceptable Alternative Method in Treatment of Acne Scars?, Medical archives (Sarajevo, Bosnia and Herzegovina) (2015)
45. Preparation and Physicochemical Evaluation of Benzoyl Peroxide 5% Foamable Emu Oil Emulsion, Jundishapur Journal of Natural Pharmaceutical Products (2015)
46. Staphylococcus Aureus in Acne Pathogenesis: A Case-Control Study, North American Journal of Medical Sciences (2012)